KEYNOTE-119

NCT02555657 📎

Regimen

Experimental
Pembrolizumab 200 mg Q3W monotherapy until progression.
Control
Investigator's choice single-agent chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine).

Population

Metastatic triple-negative breast cancer previously treated with 1-2 prior systemic regimens for metastatic disease.

Key finding

KEYNOTE-119 showed pembrolizumab monotherapy did NOT improve OS over chemotherapy in pretreated metastatic TNBC, even in PD-L1 CPS>=10 subgroup. Negative trial.

Source: PMID 33676601

Timeline

  • Publication: 2021 Apr

Guideline citations

  • NCCN BREAST